Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 3
1983 4
1984 2
1985 6
1987 5
1988 4
1989 5
1990 7
1991 10
1992 6
1993 6
1994 14
1995 14
1996 19
1997 20
1998 13
1999 14
2000 19
2001 21
2002 33
2003 29
2004 46
2005 51
2006 77
2007 70
2008 100
2009 101
2010 117
2011 178
2012 221
2013 215
2014 267
2015 283
2016 342
2017 365
2018 452
2019 586
2020 697
2021 819
2022 1026
2023 940
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

6,496 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: ren z. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Cilia-related diseases.
Ren Z, Mao X, Wang S, Wang X. Ren Z, et al. J Cell Mol Med. 2023 Oct 13. doi: 10.1111/jcmm.17990. Online ahead of print. J Cell Mol Med. 2023. PMID: 37830491 Free article. Review.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: ren z. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Drugs for treating myocardial fibrosis.
Ren Z, Zhang Z, Ling L, Liu X, Wang X. Ren Z, et al. Front Pharmacol. 2023 Sep 12;14:1221881. doi: 10.3389/fphar.2023.1221881. eCollection 2023. Front Pharmacol. 2023. PMID: 37771726 Free PMC article. Review.
Gut microbiota and cardiac arrhythmia.
Fan H, Liu X, Ren Z, Fei X, Luo J, Yang X, Xue Y, Zhang F, Liang B. Fan H, et al. Among authors: ren z. Front Cell Infect Microbiol. 2023 Apr 25;13:1147687. doi: 10.3389/fcimb.2023.1147687. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37180433 Free PMC article. Review.
Serial Dependence in Dermatological Judgments.
Ren Z, Li X, Pietralla D, Manassi M, Whitney D. Ren Z, et al. Diagnostics (Basel). 2023 May 17;13(10):1775. doi: 10.3390/diagnostics13101775. Diagnostics (Basel). 2023. PMID: 37238260 Free PMC article.
Role of the CXCR6/CXCL16 axis in autoimmune diseases.
Bao N, Fu B, Zhong X, Jia S, Ren Z, Wang H, Wang W, Shi H, Li J, Ge F, Chang Q, Gong Y, Liu W, Qiu F, Xu S, Li T. Bao N, et al. Among authors: ren z. Int Immunopharmacol. 2023 Aug;121:110530. doi: 10.1016/j.intimp.2023.110530. Epub 2023 Jun 20. Int Immunopharmacol. 2023. PMID: 37348231 Review.
6,496 results